Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 00:37 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Prophylactic Analgesia for Bladder Botox Injections
NCT06514430 · Montefiore Medical Center · PHASE4 · withdrawn · last registry update 2025-07-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “It was determined that it would be impracticable to conduct this study as a randomized trial. Study has been repurposed as a non-randomized study.” | – | Registry record, Montefiore Medical Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against SCN1A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-06-26Also stopped (terminated): Tsai-Wei Huang, a drug against SCN1A (NCT05625854)
- 2026-05-26Results posted on the registry: Eli Lilly and Company, Orforglipron + Midazolam (NCT06704763)
- 2026-05-18Results posted on the registry: University of Alabama at Birmingham, Psilocybin + Diphenhydramine (NCT02037126)
- 2026-05-15Phase 3 first posted: Cairo University, phenytoin cream (NCT07590375)
- 2026-05-13Also stopped (terminated): Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 + Placebo (NCT02534038)
- 2026-05-04Also stopped (terminated): Ottawa Heart Institute Research Corporation, Antiarrhythmic Drug Therapy (NCT02114528)
- 2026-04-24Results posted on the registry: National Institute on Drug Abuse (NIDA), SXC-2023 + SXC-2023 Placebo (NCT06343532)
- 2026-04-07Also stopped (suspended): University of California, Los Angeles, Psilocybin (NCT06102434)
- 2026-03-13Also stopped (withdrawn): Christopher D. Verrico, Exenatide + Placebo (NCT06252623)
- 2026-03-09Results posted on the registry: Sintetica SA, Chloroprocaine 3% eye gel + Oxybuprocaine Hydrochloride 4 Mg/mL Eye Drops (NCT05926258)
- 2026-02-06Results posted on the registry: Q2i, LLC, a drug against SCN1A (NCT05180669)
- 2026-02-06Also stopped (terminated): Q2i, LLC, a drug against SCN1A (NCT05180669)
- 2025-12-23Results posted on the registry: Johns Hopkins University, Suvorexant (dual orexin receptor antagonist) + Placebo (NCT05546515)
- 2025-12-12Results posted on the registry: Eli Lilly and Company, Imlunestrant + Repaglinide (NCT05444556)
- 2025-11-17Phase 3 first posted: Medical University of Vienna, Oxybuprocaine MDU + Oxybuprocaine SDU (NCT07230548)
- 2025-11-14Results posted on the registry: University of North Carolina, Chapel Hill, Phenobarbital Sodium Injection + Levetiracetam (NCT06081283)
- 2025-11-14Also stopped (terminated): University of North Carolina, Chapel Hill, Phenobarbital Sodium Injection + Levetiracetam (NCT06081283)
- 2025-10-30Also stopped (terminated): Tulane University School of Medicine, dronedarone 400 mg Oral Tablet + Placebo (NCT04704050)
- 2025-10-29Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., Placebo + AVP-786-28 (NCT03095066)
- 2025-10-20Also stopped (withdrawn): University of Wisconsin, Madison, a drug against SCN1A (NCT06985940)
- 2025-10-20Also stopped (withdrawn): Mclean Hospital, Lorcaserin + Placebo Oral Tablet (NCT03266939)
- 2025-10-16Results posted on the registry: Tulane University School of Medicine, dronedarone 400 mg Oral Tablet + Placebo (NCT04704050)
- 2025-10-15Results posted on the registry: Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 (NCT02446132)
- 2025-10-15Also stopped (terminated): Otsuka Pharmaceutical Development & Commercialization, Inc., AVP-786 (NCT02446132)
- 2025-09-30Results posted on the registry: VA Office of Research and Development, a drug against SCN1A (NCT03799341)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision